On the previous consideration that certain circRNAs probably participate in cetuximab resistance among KRAS wide-type CRC patients, together with the mechanism that circRNAs sponge miRNAs, we wondered whether certain circRNAs could directly target miR-30b and activate KRAS to induce cetuximab resistance in KRAS wide-type CRC patients. This evidence concerns the gene KRAS and colorectal carcinoma.